Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

tary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company's major efforts have been focused on projects targeting Raynaud's phenomenon, nail psoriasis and actinic keratosis. In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the 'Safe Harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectation or forecasts of future events. MediQuest's performance and financial results could differ materially from those reflected in these forward-looking statements due to the decisions of regulatory authorities, ability to implement its commercial plans, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may affect the forward-looking statements please contact the Company. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. MediQuest undertakes no obligation to update publicly any forward-looking statement
www.mqti.com

Contact information
Joseph K. Piper
Managing Director, Point B Capital
jpiper@pointbcap.com
206-577-7223

Media Contact: Siavash Forootan MediQuest Therapeutics, 215-238-8881, sforootan@numodacapital.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 Sanomedics ... August 2014 report by Global Research & Data Services, ... per year from 2014 through 2018, as demand for ... States is the world,s largest market for ... with advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( ... pulmonology, today announced completion of enrollment in their RENEW ... Clinical Study is the FDA-approved IDE pivotal trial for ... emphysema. It was anticipated that the study, ... 2013, would take until the end of 2014 to ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical company ... therapies for solid tumors and,hematological malignancies, today announced ... poster presentations at the AACR Annual Meeting,which will ... An oral presentation by Dr. Steven Warner ...
... A biosimilar product for,treating the negative effects ... cells of patients is safe and exhibits an ... This is the result of a clinical phase ... Pharma GmbH and the Indian manufacturer,INTAS Biopharmaceuticals Ltd. ...
Cached Medicine Technology:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 2SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 3Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 2Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 3
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... 22, 2014 During the Western United ... supply runs dangerously low, Southern Oregon’s water is proving ... despite the lowest mountain snow pack on record in ... and early autumn.* That was the observation of journalist-hikers ... book “Hiking Southern Oregon,” during an interview with water ...
(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... Steven Reinberg HealthDay ... Infants who quickly add weight and length may be showing ... suggests. In adults, certain genes have been linked to ... proportionate gains in fat and lean muscle, the researchers said. ... heavier and taller. By ages 2 and 3, however, these ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... of conventional in vitro fertilization (IVF) -- the incubation of ... in a device inside the vagina, new research suggests. ... device, called an INVOcell, might sharply cut costs for pricey ... technology more accessible to those who don,t live near big-city ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... and Erosive ... Esophagitis, OSAKA, Japan, Oct. ... and,Development Center, Inc., a wholly owned United States (U.S.) subsidiary,received notification from ... able to complete its review of the TAK-390MR New,Drug Application (NDA) by ...
... Pulse Report Released Today, SOUTH BEND, Ind., ... report released today confirms patients have heightened expectations,of ... to choose where,they receive care. Health care facilities ... experience to maintain and improve patient retention,rates. The ...
... achievement, a feature story on Mary Hall will appear on ... ... 18, 2008 -- Mary Hall, CEO of iHealthspot, Inc. a leading ... membership into Fort Lauderdale City Limits "Profiles of Excellence" in the ...
... to Care in Underserved,Communities, SAN DIEGO, Oct. ... care to underserved residents of San Diego County,La ... the,expansion of its telemedicine program, thanks to a ... used to purchase new equipment including a camera,that ...
... TB, fight other drug-resistant bacteria , , FRIDAY, Oct. 17 ... perfecting a new class of broad-spectrum antibiotics that could ... , The new antibiotics compounds -- all of which ... other bacteria -- also show promise as a more ...
... Oct. 17 /PRNewswire-FirstCall/ - The Westaim Corporation,announced ... its wholly owned,subsidiary iFire Technology Ltd. and ... sell its equipment, patents and intellectual property,for ... sale is subject to,several conditions, including iFire ...
Cached Medicine News:Health News:FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR 2Health News:Report Confirms Consumer Selection is a Driving Force in Health Care Today 2Health News:Report Confirms Consumer Selection is a Driving Force in Health Care Today 3Health News:Mary Hall, CEO of iHealthSpot, Inc., is Awarded Membership Into Fort Lauderdale City Limits "Profiles of Excellence" 2Health News:La Maestra Community Health Centers Expands Telemedicine Program 2Health News:La Maestra Community Health Centers Expands Telemedicine Program 3Health News:Scientists Hot on Trail of New Antibiotics 2Health News:Westaim announces sale of iFire Technology Ltd. assets 2
... The Sphincter of Oddi ... (PNET) works with the Polygraf™ ... and analyze pressure signals from ... The PNET software and Polygraf ...
... VoiceControl is a unique tool ... voice commands to activate shortcut ... eliminating the need to perform ... you can devote your full ...
... Analysis for POLYGRAM NET™ works with the ... analyze multichannel EGG signals. The EGG analysis ... by performing an automatic electrode impedance check ... beginning of a recording. If the electrode ...
... POLYGRAM NET™ (PNET) works with the ... analyze pressure and EMG signals from ... graphic format. The PNET software and ... or water-perfused manometry catheters as well ...
Medicine Products: